ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effectiveness of Preemptive Therapy in the Prevention of Cytomegalovirus (CMV) Disease in High-Risk (Donor Seropositive/Recipient Seronegative) Liver Transplant Recipients

J. A. Morillas, K. Brizendine

Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2020 American Transplant Congress

Abstract number: A-194

Keywords: Cytomeglovirus, Liver transplantation, Monitoring, Outcome

Session Information

Session Name: Poster Session A: All Infections (Excluding Kidney & Viral Hepatitis)

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Guidelines recommend preemptive therapy (PET) as one strategy for prevention of CMV disease in high risk liver transplant recipients (LTR). However, questions have been raised about feasibility and highly precise logistic requirements particularly in active centers with large volumes.

*Methods: Retrospective cohort study in high risk LTR (November 2016 – December 2018). Blood CMV DNA PCR was performed weekly during first 90d; every 1-2 weeks for 3m and then monthly. Antiviral was started for any level of viremia early post-transplant until 2 consecutive negative tests. Primary outcomes were incidence of CMV infection (viremia, regardless of symptoms) and disease (syndrome or end-organ invasive disease).

*Results: 58 LTR were evaluated. Mean age was 55.8±11.3. Mean MELD was 22±7.4. Nonalcoholic steatohepatitis cirrhosis (25.8%) was common followed by alcoholic cirrhosis (20.6%). 51.7% received ATG induction. 55/58 (94.8%) patients met all weekly CMV levels during first 90d. Only 1 LTR missed few measurements during subsequent months. CMV infection occurred in 51/58 (87.9%) during first 90d, 23/56 (41.1%) during subsequent 3 months, and 6/55 (10.9%) after 6 months post-LT. Median time to first detection of CMV was 26d (IQR, 22-32). 12.1% LTRs did not have any CMV infection. The incidence of CMV disease was 6.9% (3 CMV syndromes; 1 CMV hepatitis), with a median time of 32d (IQR, 27.2-36) post-LT. LTR with hepatitis lacked CMV levels for 1 month and had a peak of 1251560 IU/mL upon presentation. No late-onset CMV disease was documented. 100% of LTR with first CMV infection were treated regardless of CMV level. Valganciclovir was the most common therapy. 22.4% (11/49) of subsequent asymptomatic viremias (median CMV level 204, IQR 187-379) were monitored without any treatment and spontaneously resolved after a median time of 7d (IQR 6.5-19). 3 cases of resistant CMV infection were documented with UL97 gene mutations [A594V (2) and deletion 599-601 (1)]. Bacterial/ fungal infection occurred in 13/58 (22.4%). 19/58 (32.7%) LTR developed acute rejection; 13/19 (68.4%) occurred 60d after CMV infection. 1-year mortality and graft failure were 10.3% and 5.1%, respectively.

*Conclusions: PET is feasible even with large numbers of high risk LTR. CMV infection is common early post-LT (3m); however, CMV disease is not. The proportion of LTR with important outcomes such as late-onset CMV disease, resistant CMV, bacterial/ fungal infections, acute rejection, graft failure, and death was favorable in this PET cohort.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Morillas JA, Brizendine K. Effectiveness of Preemptive Therapy in the Prevention of Cytomegalovirus (CMV) Disease in High-Risk (Donor Seropositive/Recipient Seronegative) Liver Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effectiveness-of-preemptive-therapy-in-the-prevention-of-cytomegalovirus-cmv-disease-in-high-risk-donor-seropositive-recipient-seronegative-liver-transplant-recipients/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences